TN2013000442A1 - FORMULATION FOR ANTI-α4β7 ANTIBODY - Google Patents

FORMULATION FOR ANTI-α4β7 ANTIBODY

Info

Publication number
TN2013000442A1
TN2013000442A1 TNP2013000442A TN2013000442A TN2013000442A1 TN 2013000442 A1 TN2013000442 A1 TN 2013000442A1 TN P2013000442 A TNP2013000442 A TN P2013000442A TN 2013000442 A TN2013000442 A TN 2013000442A TN 2013000442 A1 TN2013000442 A1 TN 2013000442A1
Authority
TN
Tunisia
Prior art keywords
antibody
a4ss7
formulations
formulation
vivo
Prior art date
Application number
TNP2013000442A
Other languages
French (fr)
Inventor
Willow Diluzio
Nobel T Truong
Csanad M Varga
Vaithianathan Palaniappan
Jason Brown
Irving H Fox
Catherine Scholz
Original Assignee
Millennium Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US2012/036072 external-priority patent/WO2012151248A2/en
Application filed by Millennium Pharm Inc filed Critical Millennium Pharm Inc
Publication of TN2013000442A1 publication Critical patent/TN2013000442A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants

Abstract

Antibody formulations are described comprising a mixture of a non-reducing sugar, an anti-a4ss7 antibody and at least one amino acid. The disclosed formulations have improved stability, reduced aggregate formation, and may retard degradation of the anti-a4ss7 antibody therein or exhibit any combinations thereof. The present invention further provides a safe dosing regimen of these antibody formulations that is easy to follow, and which results in a therapeutically effective amount of the anti-a4ss7 antibody in vivo.
TNP2013000442A 2012-01-12 2013-10-29 FORMULATION FOR ANTI-α4β7 ANTIBODY TN2013000442A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261585859P 2012-01-12 2012-01-12
PCT/US2012/036072 WO2012151248A2 (en) 2011-05-02 2012-05-02 FORMULATION FOR ANTI-α4β7 ANTIBODY

Publications (1)

Publication Number Publication Date
TN2013000442A1 true TN2013000442A1 (en) 2015-03-30

Family

ID=54360587

Family Applications (1)

Application Number Title Priority Date Filing Date
TNP2013000442A TN2013000442A1 (en) 2012-01-12 2013-10-29 FORMULATION FOR ANTI-α4β7 ANTIBODY

Country Status (2)

Country Link
EA (2) EA034583B1 (en)
TN (1) TN2013000442A1 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4041761A4 (en) * 2019-10-11 2023-10-25 Dr. Reddy's Laboratories Limited Stable formulation of integrin antibody

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7147851B1 (en) * 1996-08-15 2006-12-12 Millennium Pharmaceuticals, Inc. Humanized immunoglobulin reactive with α4β7 integrin
US20010046496A1 (en) * 2000-04-14 2001-11-29 Brettman Lee R. Method of administering an antibody
CA2629147A1 (en) * 2005-11-17 2007-05-31 Millennium Pharmaceuticals, Inc. Humanized immunoglobulin reactive with .alpha.4.beta.7 integrin

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4041761A4 (en) * 2019-10-11 2023-10-25 Dr. Reddy's Laboratories Limited Stable formulation of integrin antibody

Also Published As

Publication number Publication date
EA201992881A2 (en) 2020-09-30
EA201992881A3 (en) 2020-12-30
EA034583B1 (en) 2020-02-21
EA201892377A1 (en) 2019-03-29

Similar Documents

Publication Publication Date Title
PH12020500336A1 (en) FORMULATION FOR ANTI-a4á7 ANTIBODY
PH12019501662A1 (en) FORMULATION FOR ANTI-a4á7 ANTIBODY
MX2019000586A (en) Treatment of amd using aav sflt-1.
WO2014062733A3 (en) Substituted benzene compounds
WO2014062720A3 (en) Methods of treating cancer
MX348823B (en) Stable formulations of linaclotide.
EA201590491A1 (en) IMMUNOGENIC COMPOSITION
MX344846B (en) Combination of active loaded granules with additional actives.
UA116889C2 (en) COMPOSITION COMPRISING A MIXTURE OF CD95-Fc ISOFORMS
PH12015502717A1 (en) Anti-fibrogenic compounds, methods and uses thereof
TN2013000442A1 (en) FORMULATION FOR ANTI-α4β7 ANTIBODY
TN2013000455A1 (en) FORMULATION FOR ANTI-α4β7 ANTIBODY
IN2013MU02584A (en)
UA112984C2 (en) COMPOSITION OF ANTI-α4β7 ANTIBODY
WO2014141298A3 (en) Stable pharmaceutical composition of fingolimod
TR201203086A2 (en) Pharmaceutical dosage form comprising cefixime and clavulanic acid.